12,372 trials
Gastroenteritis · Rotavirus
Primary: The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA — 82.35 Percentage of…
Cerebrovascular Accident
Primary: Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal) — 45; 32 patients — p=0.097
Ankylosing Spondylitis
Primary: Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20)…
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Coefficient of Fat Absorption (%) — 47.41; 82.81 Percentage — p=<0.001
Antifungal Prophylaxis of Invasive Fungal Infections
Primary: Success at Day 180: Percent of Responders (Randomization Strata) — 59.1; 44.7; 52.5; 25.9 percent of participants
Type 2 Diabetes
Primary: Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4 — 177.5; 181.2; 163.8; 184.2 mg/dL — p=0.0001
Anemia
Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants
Diabetes Mellitus
Primary: Percent Change From Baseline in Glycosylated Hemoglobin — -1.83; -0.96; -0.99 percentage of Glycosylated Hemoglobin — p=<0.0001
Hypercholesterolemia · Diabetes Mellitus, Type 2 · Coronary Disease
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005
Cervical Cancer · Genital Warts
Primary: Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3 — 423; 428; 320; 0 Subjects — p=<0.001
Neoplasms, Prostate
Primary: Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach) — 578; 435; 280; 224 participants — p=<0.0001
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 337; 342; 345; 346…
Relapsing Remitting Multiple Sclerosis (RRMS)
Primary: Visual Analog Scale (VAS) of Patient Reported Pain: Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 30 Minutes Post-injection Timepoints — 0.43…
Multiple Myeloma
Primary: Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.
Multiple Myeloma
Primary: Time to Tumor Progression (TTP) — 60.1; 20.1 Weeks